Open AccessEfficacy of imatinib mesylate in advanced medullary thyroid carcinoma
Author(s) -
Karin FrankRaue,
M. Fabel,
Stefan Delorme,
Uwe Haberkorn,
Friedhelm Raue
Publication year - 2007
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-06-0695
Subject(s) - medicine , imatinib mesylate , mesylate , gastroenterology , tyrosine kinase inhibitor , rash , progressive disease , thyroid carcinoma , nausea , tyrosine kinase , imatinib , oncology , thyroid , chemotherapy , cancer , receptor , chemistry , myeloid leukemia , organic chemistry
Medullary thyroid carcinoma (MTC) is often associated with gain-of-function mutations in the RET proto-oncogene, which is found in all hereditary cases and most sporadic cases. The activated RET receptor tyrosine kinase can be inhibited by tyrosine kinase inhibitors in vitro. We evaluated the efficacy of treatment with imatinib mesylate, a tyrosine kinase inhibitor, in patients with advanced MTC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom